Poly Medicure Posts Q1 Revenue of 5.25 Bln Rupees

June-Financial Performance and Revenue Growth

On August 7, 2026, Poly Medicure Limited officially released its unaudited consolidated financial results for the first quarter of fiscal year 2027. According to regulatory filings submitted to stock exchanges, Poly Medicure achieved a consolidated revenue from operations totaling 5.25 billion rupees for the quarter ended in June.

The company registered a consolidated net profit of 860.3 million rupees for the quarter. The robust bottom-line performance reflects sustained growth across specialized verticals including infusion therapy, oncology, renal care, and vascular access devices, alongside strategic contributions from recent European acquisitions such as PendraCare and Citieffe.

Operational Context and Market Integration

The latest financial disclosures highlight Poly Medicure's ongoing focus on high-margin product innovations, advanced manufacturing capabilities, and global footprint expansion. As a premier Indian medical technology exporter, the firm continues to navigate evolving international healthcare demands while capitalizing on domestic import-substitution trends.

Industry analysts tracking the medical equipment sector note that integrating overseas subsidiaries while maintaining strong domestic momentum allows Poly Medicure to safeguard operational margins and expand its global distribution network across more than 100 countries.

Impact on Investors and Healthcare Stakeholders

For investors, clinical partners, and market participants, the reported June-quarter metrics provide essential visibility into the company's scaling trajectory and profitability.

• Investors: The consolidated net profit of 860.3 million rupees, underpinned by an operational revenue of 5.25 billion rupees, demonstrates healthy financial health and steady cash flow generation.

• Healthcare Providers: Consistent output of critical medical consumables ensures uninterrupted supply chains for hospitals and institutional buyers worldwide.

Official Sources Section

• According to official corporate announcements and regulatory filings submitted by Poly Medicure Limited.

• Market disclosures monitored via the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE).

Quote Section

"According to officials, the board-approved consolidated financial results for the June quarter reflect resilient operational execution, strong domestic market traction, and successful strategic integration across global healthcare segments."

Why It Matters

The release of the June-quarter financial statement by Poly Medicure illustrates how leading medical device manufacturers sustain growth amidst shifting global trade dynamics. By achieving 5.25 billion rupees in operating revenue and 860.3 million rupees in net profit, Poly Medicure underscores its capacity to fund continuous research and development while meeting high-volume clinical demands.

Key Facts at a Glance

• Consolidated Revenue: 5.25 billion rupees for the June quarter.

• Consolidated Net Profit: 860.3 million rupees.

• Reporting Period: Quarter ended June 30, 2026 (Q1 FY27).

• Filing Date: Financial results approved and published on August 7, 2026.

FAQ Section

1. What was Poly Medicure's consolidated revenue for the June quarter?

Poly Medicure reported a consolidated revenue from operations of 5.25 billion rupees for the quarter.

2. What was the net profit recorded by Poly Medicure in Q1?

The company registered a consolidated net profit of 860.3 million rupees for the June quarter.

3. Which sectors contribute to Poly Medicure's primary business operations?

The company specializes in manufacturing medical devices, including infusion therapy, vascular access, renal care, and critical care equipment.

4. Where are these financial results officially filed?

The results are filed and made publicly available through regulatory disclosures on the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE).

Source: Poly Medicure Corporate Disclosures, National Stock Exchange of India, Bombay Stock Exchange